Inovio Pharmaceuticals (INO) Bullish Stance Reiterated at Piper Jaffray Amid Explosive Zika Spread
Tweet Send to a Friend
Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and $31 price target on Inovio Pharmaceuticals (NASDAQ: INO), highlighting the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
